Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–92 of 92 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: debridement/dressing of wound Clear all

Conditions: Diabetic Foot Ulcer
Interventions: Dual-layer perinatal tissue allograft, Three-layer fenestrated perinatal tissue allograft, Standard of care; Other
Lead sponsor: Samaritan Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Monroe, North Carolina

Conditions: Venous Leg Ulcer
Interventions: Membrane Wrap™, Standard of Care; Device · Other
Lead sponsor: BioLab Holdings; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 9
States / cities: Mesa, Arizona • San Franciso, California • DeLand, Florida + 6 more

Conditions: Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis, Wound Heal, Wounds, Venous Insufficiency of Leg, Non-healing Wound
Interventions: TR987 0.1% gel + Standard of Care, Standard of care; Drug · Other
Lead sponsor: TR Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 33
States / cities: Tucson, Arizona • Castro Valley, California • Fresno, California + 27 more

Conditions: Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer, Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer), Chronic Wound Care
Interventions: Platelet Rich Plasma; Device
Lead sponsor: Estar Medical dba Medical Technologies, LTD; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Corpus Christi, Texas

Conditions: Chronic Pressure Ulcers
Interventions: PuraPly® Antimicrobial Wound Matrix, SOC for Pressure Ulcers; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Lake Success, New York • Mineola, New York

Conditions: Diabetic Foot Ulcer
Interventions: NeoThelium FT (HCT/P 361); Other
Lead sponsor: NuScience Medical Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Alexandria, Louisiana • Leesville, Louisiana • Many, Louisiana

Conditions: Wound Heal, Diabetic Foot Ulcer
Interventions: EDX110; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Phoenix, Arizona • Santa Ana, California • Vista, California + 1 more

Conditions: Trauma-related Wound, Burn, Partial Thickness
Interventions: Procellera®, Standard of Care; Device · Other
Lead sponsor: The Metis Foundation; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft, Biologic
Interventions: All sentinel cohort participants will receive biologic plus SOC. who receive at least one treatment of the biologic plus SOC and complete the treatment period of 12 weeks., Standard wound care for diabetic foot ulcers, Participants in the randomized phase are assigned by randomization (2:1) to BIOxHEAL plus SOC or SOC alone. once weekly for up to 12 weeks or until complete ulcer closure; Biological · Other
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boardman, Ohio

Conditions: Pressure Ulcer
Interventions: BlastX with negative pressure therapy; Device
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Kittanning, Pennsylvania

Conditions: Diabetic Foot Ulcer (DFU)
Interventions: FoundationDRS Solo, Standard of Care; Other
Lead sponsor: Samaritan Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Wound, Nonpenetrating
Interventions: Transpose ® RT System, debridement/dressing of wound; Device · Other
Lead sponsor: InGeneron, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Venous Leg Ulcer
Interventions: Affinity; Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Diabetic Foot Ulcers
Interventions: DermaPure™, Standard care; Other
Lead sponsor: TRx Wound Care Limited; Industry
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 7
States / cities: Phoenix, Arizona • Miami, Florida • New York, New York + 3 more

Conditions: Diabetic Foot Ulcer
Interventions: Tenex TXB MicroTip Ultrasound system plus SOC, Standard of Care for diabetic foot ulcer; Device · Other
Lead sponsor: Tenex Health Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Mobile, Alabama • St. George, Utah

Conditions: Open Wound
Interventions: Standard of Care, NeoThelium FT; Other
Lead sponsor: NuScience Medical Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Denham Springs, Louisiana • Hammond, Louisiana • Lafayette, Louisiana + 11 more

Conditions: Varicose Ulcer, Venous Insufficiency
Interventions: AmnioExCel dressing and compression therapy, SOC alginate dressing and compression therapy; Biological · Procedure
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Diabetic Foot Ulcer
Interventions: Standard of Care, NeoThelium FT; Other
Lead sponsor: NuScience Medical Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Alexandria, Louisiana • Franklinton, Louisiana • Hammond, Louisiana + 5 more

Conditions: Venous Leg Ulcer
Interventions: Dermagraft(R), Profore; Device
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 34
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more

Conditions: Diabetic Foot Ulcer
Interventions: Standard of Care, PuraPly AM, PuraPly XT; Other · Device
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Clevland, Ohio

Search by objective public record fields.

Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers.

Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population

Tissue Repair Gel in Venous Leg Ulcers (US)

Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.

PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Diabetic Foot Ulcers

EDX110 Randomized Control Trial for Treatment of DFUs

Procellera® Compared to Standard of Care Treatment in Mitigating Biofilm Formation in Acute Trauma and Burn Wounds

a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers

Evaluating Blast-X® in Combination With Negative Pressure Wound Therapy

Evaluating the Efficacy of FoundationDRS Solo in Addition to Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers

Healing Chronic Venous Stasis Wounds With Autologous Cell Therapy

Clinical Study Of Affinity Versus SOC In The Management Of VLUs

A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers

Prospective, Multicenter, RCT of the Tenex Ultrasound System

Evaluating the Efficacy of NeoThelium FT in the Treatment of Chronic Open Wounds

Amniotic Membrane Allograft Application in the Management of Venous Leg Ulcerations

Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers

Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers